New drug targets Life-Threatening immune storm in rheumatic patients

NCT ID NCT07208058

Recruiting now Disease control Sponsor: TJ Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This phase 3 trial tests a drug called plonmarlimab in 30 adults with a severe immune overreaction (macrophage activation syndrome) linked to rheumatic diseases that hasn't responded to prior treatment. Participants receive weekly IV infusions for 8 weeks. The main goal is to see if the drug can control the overactive immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Plonmarlimab (a drug given by IV injection)
What this could lead to: If it works, this could offer a new treatment option for people with severe, hard-to-treat macrophage activation syndrome, a life-threatening complication of rheumatic diseases.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY RHEUMATIC AND IMMUNOLOGIC DISEASE-ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macrophage activation syndrome Recurrence secondary hemophagocytic lymphohistiocytosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY RHEUMATIC AND IMMUNOLOGIC DISEASE-ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Contacts and locations

Locations

Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, China
Children's Hospital of Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China
Henan Children's Hospital Zhengzhou Children's Hospital
RECRUITING

Zhengzhou, Henan, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Peking University People's Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
The First Affiliated Hospital of China Medical University
WITHDRAWN

Shenyang, Liaoning, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITING

Wenzhou, Zhejiang, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, Guangxi, China
The Second Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, China
Tianjin Medical University General Hospital
WITHDRAWN

Tianjin, Tianjin Municipality, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China